← Back to Home

New Lung Cancer Drug’s Survival Curve Continues to Shift in a Favorable Direction, but Key Statistics Remain Undisclosed

The hazard ratio for death fell to 0.76 with ivonescimab plus chemotherapy in a global Phase 3 trial of EGFR-mutant lung cancer, with consistent trends among Eastern and Western patients. However, the updated confidence interval and median survival have not yet been disclosed, and whether this update can change the regulatory assessment will still depend on the complete data.

By SURL BioNews

For patients with EGFR-mutant non-small cell lung cancer whose disease continues to worsen after targeted therapy, the next step in treatment often presents the challenge of limited options and benefits that are not sufficiently durable. Summit Therapeutics has announced an updated analysis of the global Phase 3 HARMONi trial: ivonescimab plus chemotherapy reduced the overall hazard ratio for death to 0.76 compared with chemotherapy alone, continuing the previously observed trend of gradually improving survival and adding supporting evidence for the therapy, which is undergoing US regulatory review.

The trial enrolled patients with EGFR-mutant, non-squamous non-small cell lung cancer whose disease had progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor. Ivonescimab is a bispecific antibody targeting both PD-1 and VEGF, designed to both relieve tumor-mediated suppression of the immune system and block angiogenic signals that help tumors grow. In HARMONi, it was used in combination with chemotherapy, while the control group received chemotherapy plus placebo.

Changes in the survival data are the core of this update. At the primary analysis in April 2025, median overall survival was 16.8 months in the combination treatment group and 14.0 months in the control group, with a hazard ratio for death of 0.79. However, the 95% confidence interval was 0.62 to 1.01 and the P value was 0.057, failing to cross the prespecified threshold for statistical significance. By September of that year, the hazard ratio had improved to 0.78, with a 95% confidence interval of 0.62 to 0.98 and a nominal P value of 0.0332. In the latest analysis, with data through June 2026, the hazard ratio in the intention-to-treat population fell further to 0.76.

Geographic consistency is a signal the company particularly emphasized in this update. According to documents Summit submitted to the US Securities and Exchange Commission, the hazard ratio for death among Western patients was also 0.76, with median follow-up reaching 23.2 months; median follow-up among Asian patients was 32.7 months. This data cutoff occurred after most Western patients had discontinued treatment or completed two years of therapy, making the data more mature than in earlier analyses. However, the company has not yet disclosed updated median survival, the confidence interval, or the P value, and the complete results are expected to be presented at a future medical meeting.

Regarding safety, Summit said no new safety signals were identified, but the currently available public information is insufficient to further assess different categories of serious adverse events, discontinuation rates, or differences between Eastern and Western populations. More importantly, movement of the hazard ratio in a favorable direction does not mean that statistical significance has been demonstrated. In the absence of complete statistical data, the distribution of subsequent treatments, and more detailed safety data, the more reasonable interpretation at this stage is that the survival benefit shows a persistent and geographically consistent trend, rather than a definitive conclusion.

The regulatory clock is already running. The US Food and Drug Administration is reviewing Summit’s application and is scheduled to make a decision by November 14. The company has also submitted the latest analysis to the FDA. The review will focus not only on the single figure of 0.76, but also on whether the prespecified approach to subsequent analyses after the primary analysis failed to reach statistical significance, data maturity, magnitude of benefit, and safety together form sufficiently compelling evidence. For patients, the truly critical question is not whether the curves appear better, but whether the difference can be maintained in the complete data and translate into a credible and clinically meaningful extension of survival.

References

  1. Summit Therapeutics
  2. CancerNetwork
  3. U.S. Securities and Exchange Commission